Skip to main content

Table 3 Relationship between demographic, clinical characteristics and anticoagulant therapy in all patients and those with high risk of stroke

From: Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study

VariablesClassificationAll patients n(%)z/χ2p valuepatients with high risk of stroke n(%)z/χ2p value
OACno OACOACno OAC
GenderMale114 (37.5)198 (63.5)1.7950.180 α78 (35.8)140 (64.2)0.6020.438 α
Female88 (31.3)193 (68.7)  69 (32.2)145 (67.8)  
PaymentSelf-paying32 (24.6)98 (75.4)6.6180.010 α15 (21.1)56 (78.9)6.2990.012 α
Medical insurance170 (36.7)293 (63.3)  132 (36.6)229 (63.4)  
Age< 6031 (40.8)45 (59.2)−3.0170.003 β11 (73.3)4 (26.7)24.3040.000 β
60~6957 (36.3)100 (63.7)  35 (39.3)54 (60.7)  
70~7981 (39.5)124 (60.5)  68 (39.1)106 (60.9)  
≥8033 (21.3)122 (78.7)  33 (21.4)121 (78.6)  
EducationPrimary school or below103 (32.6)213 (67.4)−0.2900.771 β84 (32.7)173 (67.3)1.4020.496 β
Junior high school58 (40.0)87 (60.0)  35 (39.3)54 (60.7)  
Senior high school and above41 (31.1)91 (68.9)  28 (32.6)58 (67.4)  
AF typeParoxysmal122 (32.0)259 (68.0)−1.6970.090 β82 (31.8)176 (68.2)2.2980.317 β
Persistent60 (34.9)112 (65.1)  50 (35.7)90 (64.3)  
Permanent20 (50.0)20 (50.0)  16 (45.7)19 (54.3)  
Duration< 5 years129 (38.5)206 (61.5)6.7680.009 α89 (38.2)144 (61.8)4.7740.029 α
≥5 years73 (28.3)185 (71.7)  58 (29.1)141 (70.9)  
Symptom of severityAsymptomatic28 (45.9)33 (54.1)−0.9510.342 β20 (46.5)23 (53.5)4.1430.246 β
Mild108 (32.3)226 (67.7)  77 (32.5)160 (67.5)  
Moderate55 (32.5)114 (67.5)  42 (31.6)91 (68.4)  
Severe11 (37.9)18 (62.1)  8 (42.1)11 (57.9)  
HypertensionYes129 (35.9)230 (64.1)1.6860.194 α115 (37.5)192 (62.5)5.5650.018 α
No72 (30.8)162 (69.2)  32 (25.6)93 (74.4)  
Vascular diseaseYes7 (25.9)20 (74.1)0.8020.371 α18 (28.1)46 (71.9)1.1660.280 α
No194 (34.3)372 (65.7)  129 (35.1)239 (64.9)  
Diabetes mellitusYes46 (39.0)72 (61.0)1.7020.192 α46 (40.4)68 (59.6)2.7580.097 α
No155 (32.6)320 (67.4)  101 (31.8)217 (68.2)  
Coronary heart diseaseYes41 (29.7)97 (70.3)1.4060.236 α36 (31.6)78 (68.4)0.4140.520 α
No160 (35.2)295 (64.8)  111 (34.9)207 (65.1)  
Heart failureYes36 (37.9)59 (62.1)0.5370.464 α30 (37.0)51 (63.0)0.4020.526 α
No155 (32.6)320 (67.4)  117 (33.3)234 (66.7)  
HyperlipidemiaYes8 (21.1)30 (78.9)2.9890.084 α5 (20.0)20 (80.0)2.3260.127 α
No193 (34.8)362 (65.2)  142 (34.9)265 (65.1)  
StrokeYes19 (28.8)47 (71.2)0.8650.352 α19 (29.2)46 (70.8)0.5880.443 α
No182 (34.5)345 (65.5)  128 (34.9)239 (65.1)  
Impaired renal/liver functionYes13 (44.8)16 (55.2)1.6260.202 α12 (44.4)15 (55.6)1.3920.238 α
No188 (33.3)376 (66.7)  135 (33.3)270 (66.7)  
HAS-BLED, score< 3180 (33.9)351 (66.1)0.0620.803 α125 (33.8)245 (66.2)0.0680.794 α
≥322 (35.5)40 (64.5)  22 (35.5)40 (64.5)  
CHA2DS2-VASc, scoreMale: 0~2; female: 0~156 (34.8)105 (65.2)0.0620.804 α    
Male ≥3; female ≥2155 (35.9)277 (64.1)      
  1. Abbreviations: AF Atrial fibrillation, CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years,diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65–74 years, sex category (female), HAS-BLED Hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, NOAC Non-vitamin K antagonist oral anticoagulant
  2. α: χ2-test; β: Wilcoxon rank-sum test